Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.16/2258
Registo completo
Campo DCValorIdioma
degois.publication.titleRevista da Sociedade Portuguesa de Dermatologia e Venereologiapt_PT
dc.contributor.authorTorres, T.-
dc.contributor.authorFilipe, P.-
dc.identifier.citationRevista SPDV 2018; 76(1):53-64pt_PT
dc.description.abstractABSTRACT – Psoriasis is a chronic, inflammatory, immune-mediated, potentially disfiguring and disabling skin disorder, affecting over 100 million individuals worldwide. Calcipotriol plus betamethasone fixed-combination (0.005% Cal/0.064% BD) is the recommended topical treatment for psoriasis. However, topical treatments are associated to lack of efficacy and low adhesion rates due to poor cosmetic characteristics’ formulations, and vehicle issues. To answer the need for improving patients’ acceptability and adherence, an innovative Cal/BD aerosol foam formulation was developed for the topical treatment of adults with plaque psoriasis. Phase II and III clinical trials have consistently shown that the two-compound formulation is more effective and safer than its individual ingredients in the same vehicle. Cal/BD aerosol foam formulation has proved higher efficacy in clinical studies, and a pooled analysis of the main clinical studies has demonstrated that this does not occur at the safety profile expense. Furthermore Cal/BD aerosol foam has shown a significantly improved efficacy compared with more traditional formulations, such as ointments, gels, and lotions. The improved efficacy and safety profile of this new formulation, together with the once-daily treatment, a moreacceptable tolerability profile, and an early and rapid response, offers improved convenience and better acceptance over the twice--daily applications required for the respective monotherapies, which may improve adherence to treatment, leading to faster and greater improvements in HR-QoL, representing a useful therapeutic option to the management of patients with plaque psoriasis. Further clinical investigations to explore the possibility of Cal/BD aerosol foam treatment ability to provide long-term psoriasis’ management are required.pt_PT
dc.publisherSociedade Portuguesa de Dermatologia e Venereologiapt_PT
dc.subjectBetamethasone/administration & dosagept_PT
dc.subjectBetamethasone/analogs & derivativespt_PT
dc.subjectCalcitriol/administration & dosagept_PT
dc.subjectCalcitriol/analogs & derivativespt_PT
dc.subjectPsoriasis/drug therapypt_PT
dc.titleNew Calcipotriol/Betamethasone Dipropionate Foam Formulation for the Treatment of Psoriasis: An Overviewpt_PT
dc.title.alternativeA Nova Formulação de Calcipotriol/Dipropionato de Betametasona em Espuma Cutânea para o Tratamento da Psoríasept_PT
Aparece nas colecções:SD - Artigos publicados em revistas não indexadas na Medline

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
New Calcipotriol Betamethasone Dipropionate.pdf305,4 kBAdobe PDFVer/Abrir

FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.